SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC receives CRL from USFDA for Taclantis

12 Feb 2020 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the New Drug Application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised. As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.

SPARC is an international pharmaceutical company engaged in research and development of drugs and  delivery systems.

Sun Pharma Adv. Res Share Price

172.85 5.90 (3.53%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 458.00
Indegene 529.65
CMS Info Systems 290.00
JITF Infralogistics 307.90
Sagility 44.18
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×